Literature DB >> 26462805

PPARγ Regulation in Hypertension and Metabolic Syndrome.

Madeliene Stump1,2, Masashi Mukohda3, Chunyan Hu3, Curt D Sigmund4,5,6,7.   

Abstract

Dysregulation of peroxisome proliferator-activated receptor gamma (PPARγ) activity leads to significant alterations in cardiovascular and metabolic regulation. This is most keenly observed by the metabolic syndrome-like phenotypes exhibited by patients carrying mutations in PPARγ. We will summarize recent findings regarding mechanisms of PPARγ regulation in the cardiovascular and nervous systems focusing largely on PPARγ in the smooth muscle, endothelium, and brain. Canonically, PPARγ exerts its effects by regulating the expression of target genes in these cells, and we will discuss mechanisms by which PPARγ targets in the vasculature regulate cardiovascular function. We will also discuss emerging evidence that PPARγ in the brain is a mediator of appetite and obesity. Finally, we will briefly review how novel PPARγ activators control posttranslational modifications of PPARγ and their prospects to offer new therapeutic options for treatment of metabolic diseases without the adverse side effects of thiazolidinediones which strongly activate transcriptional activity of PPARγ.

Entities:  

Keywords:  Brain; PPARγ; Posttranslational modifications; Ubiquitin ligase; Vascular function

Mesh:

Substances:

Year:  2015        PMID: 26462805      PMCID: PMC6766749          DOI: 10.1007/s11906-015-0601-x

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  92 in total

1.  PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties.

Authors:  M Amine Bouhlel; Bruno Derudas; Elena Rigamonti; Rébecca Dièvart; John Brozek; Stéphan Haulon; Christophe Zawadzki; Brigitte Jude; Gérard Torpier; Nikolaus Marx; Bart Staels; Giulia Chinetti-Gbaguidi
Journal:  Cell Metab       Date:  2007-08       Impact factor: 27.287

2.  Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production.

Authors:  Jennifer M Kleinhenz; Dean J Kleinhenz; Shaojin You; Jeffrey D Ritzenthaler; Jason M Hansen; David R Archer; Roy L Sutliff; C Michael Hart
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-07       Impact factor: 4.733

3.  Vascular smooth muscle cell peroxisome proliferator-activated receptor-γ mediates pioglitazone-reduced vascular lesion formation.

Authors:  Milton Hamblin; Lin Chang; Hengmin Zhang; Kun Yang; Jifeng Zhang; Y Eugene Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-18       Impact factor: 8.311

4.  Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.

Authors:  Angelika Lüdtke; Janine Buettner; Wei Wu; Antoine Muchir; Andreas Schroeter; Sophie Zinn-Justin; Simone Spuler; Hartmut H-J Schmidt; Howard J Worman
Journal:  J Clin Endocrinol Metab       Date:  2007-03-13       Impact factor: 5.958

5.  Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet.

Authors:  Andreas M Beyer; Willem J de Lange; Carmen M Halabi; Mary L Modrick; Henry L Keen; Frank M Faraci; Curt D Sigmund
Journal:  Circ Res       Date:  2008-07-31       Impact factor: 17.367

6.  Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.

Authors:  Mirja Tiikkainen; Anna-Maija Häkkinen; Elena Korsheninnikova; Tuulikki Nyman; Sari Mäkimattila; Hannele Yki-Järvinen
Journal:  Diabetes       Date:  2004-08       Impact factor: 9.461

7.  PPARγ: no SirT, no service.

Authors:  Frederick W Quelle; Curt D Sigmund
Journal:  Circ Res       Date:  2013-02-01       Impact factor: 17.367

8.  PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice.

Authors:  Takeshi Kanda; Jonathan D Brown; Gabriela Orasanu; Silke Vogel; Frank J Gonzalez; Juliano Sartoretto; Thomas Michel; Jorge Plutzky
Journal:  J Clin Invest       Date:  2008-12-08       Impact factor: 14.808

9.  Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA.

Authors:  Denise Kelly; Jamie I Campbell; Timothy P King; George Grant; Emmelie A Jansson; Alistair G P Coutts; Sven Pettersson; Shaun Conway
Journal:  Nat Immunol       Date:  2003-12-21       Impact factor: 25.606

10.  Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance.

Authors:  Maura Agostini; Erik Schoenmakers; Catherine Mitchell; Istvan Szatmari; David Savage; Aaron Smith; Odelia Rajanayagam; Robert Semple; Jian'an Luan; Louise Bath; Anthony Zalin; Mourad Labib; Sudhesh Kumar; Helen Simpson; Dirk Blom; David Marais; John Schwabe; Inês Barroso; Richard Trembath; Nicholas Wareham; Laszlo Nagy; Mark Gurnell; Stephen O'Rahilly; Krishna Chatterjee
Journal:  Cell Metab       Date:  2006-10       Impact factor: 27.287

View more
  10 in total

Review 1.  Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension.

Authors:  Alexandre Vallée; Bernard L Lévy; Jacques Blacher
Journal:  Curr Hypertens Rep       Date:  2018-06-09       Impact factor: 5.369

2.  A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes.

Authors:  Md Abdul Hye Khan; Lauren Kolb; Melissa Skibba; Markus Hartmann; René Blöcher; Ewgenij Proschak; John D Imig
Journal:  Diabetologia       Date:  2018-07-21       Impact factor: 10.122

Review 3.  Anti-inflammatory mechanisms of the vascular smooth muscle PPARγ.

Authors:  Masashi Mukohda; Hiroshi Ozaki
Journal:  J Smooth Muscle Res       Date:  2021

4.  Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.

Authors:  Oyunbileg Magvanjav; Yan Gong; Caitrin W McDonough; Arlene B Chapman; Stephen T Turner; John G Gums; Kent R Bailey; Eric Boerwinkle; Amber L Beitelshees; Toshihiro Tanaka; Michiaki Kubo; Carl J Pepine; Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  J Am Heart Assoc       Date:  2017-11-02       Impact factor: 5.501

5.  Effect of the Pro12Ala Polymorphism of the Peroxisome Proliferator-activated Receptor γ2 Gene on Lipid Profile and Adipokines Levels in Obese Subjects.

Authors:  E Becer; A Çırakoğlu
Journal:  Balkan J Med Genet       Date:  2017-06-30       Impact factor: 0.519

6.  Crocin prevents metabolic syndrome in rats via enhancing PPAR-gamma and AMPK.

Authors:  Mardi M Algandaby
Journal:  Saudi J Biol Sci       Date:  2020-01-27       Impact factor: 4.219

7.  PPARγ Mediates the Cardioprotective Roles of Danlou Tablet After Acute Myocardial Ischemia-Reperfusion Injury.

Authors:  Meng Wei; Mengying Guo; Xinxiu Meng; Lin Li; Hongyun Wang; Mingxue Zhang; Yihua Bei
Journal:  Front Cardiovasc Med       Date:  2022-03-25

8.  Recent findings on the cellular and molecular mechanisms of action of novel food-derived antihypertensive peptides.

Authors:  Innocent U Okagu; Timothy P C Ezeorba; Emmanuel C Aham; Rita N Aguchem; Regina N Nechi
Journal:  Food Chem (Oxf)       Date:  2022-01-25

Review 9.  Recent advances in central cardiovascular control: sex, ROS, gas and inflammation.

Authors:  Pauline M Smith; Alastair V Ferguson
Journal:  F1000Res       Date:  2016-03-31

Review 10.  Atypical Rho GTPases of the RhoBTB Subfamily: Roles in Vesicle Trafficking and Tumorigenesis.

Authors:  Wei Ji; Francisco Rivero
Journal:  Cells       Date:  2016-06-14       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.